Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Alexander Edward Kuta, III, insider at uniQure
Alexander Edward Kuta, III Insider Alerts

Get notified the next time Alexander Edward Kuta, III buys or sells uniQure stock. Enter your email address below to get our daily insider buying and selling report.

Alexander Edward Kuta, III Insider Information

VP of uniQure
Dr. Alex Kuta joined uniQure in January 2017 as Senior Vice President, Regulatory Affairs. In his current role as Executive Vice President, Operations, he is responsible for global quality and regulatory affairs, as well as GMP manufacturing at uniQure’s state-of-the-art facility in Lexington, Massachusetts. 

He joined uniQure from EMD Serono, where he served as Vice President of Research & Development Global Regulatory Affairs and where he was a member of the U.S. Leadership Team.  In this role, he was responsible for driving the strategic direction of EMD Serono’s regulatory efforts in immune-mediated diseases, oncology and regulatory CMC, as well as strengthening interactions with the U.S. Food and Drug Administration (FDA).

Prior to joining EMD Serono, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging. His previous experience includes senior roles at AMAG Pharmaceuticals and at Genzyme Corporation, where he served for 15 years in regulatory leadership positions of increasing responsibility.  Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA.   Dr. Kuta has also served as a member of the BIO Regulatory Affairs Leadership Committee, Cell and Gene Therapy Working Group and the ICH Gene Therapy Working Group.

Dr. Kuta holds a Bachelor of Science degree from Saint John's University and a Ph.D. from Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/ National Institutes of Health.

What is Alexander Edward Kuta, III's net worth?

The estimated net worth of Alexander Edward Kuta, III is at least $2.03 million as of July 15th, 2021. Dr. Kuta, III owns 74,871 shares of uniQure stock worth more than $2,031,999 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Kuta, III may own. Learn More.

How do I contact Alexander Edward Kuta, III?

The corporate mailing address for Dr. Kuta, III and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at [email protected]

Has Alexander Edward Kuta, III been buying or selling shares of uniQure?

During the last quarter, Alexander Edward Kuta, III has sold $374,760.00 in shares of uniQure stock. Most recently, Alexander Edward Kuta III sold 6,000 shares of the business's stock in a transaction on Monday, November 15th. The shares were sold at an average price of $31.81, for a transaction totalling $190,860.00.

Who are uniQure's active insiders?

uniQure's insider roster includes Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), and Alexander Kuta, III (VP).

Are insiders buying or selling shares of uniQure?

In the last twelve months, insiders at the biotechnology company sold shares 22 times. They sold a total of 126,301 shares worth more than $4,529,422.66. The most recent insider tranaction occured on November, 15th when VP Alexander Edward Kuta III sold 6,000 shares worth more than $190,860.00. Insiders at uniQure own 2.7 % of the company.

Information on this page was last updated on 11/15/2021.

Alexander Edward Kuta, III Insider Trading History at uniQure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2021Sell6,000$31.81$190,860.00View SEC Filing Icon  
10/15/2021Sell6,000$30.65$183,900.00View SEC Filing Icon  
9/21/2021Sell2,229$36.71$81,826.59View SEC Filing Icon  
9/15/2021Sell6,000$36.32$217,920.00View SEC Filing Icon  
8/16/2021Sell6,000$28.84$173,040.00View SEC Filing Icon  
7/15/2021Sell6,000$27.22$163,320.0074,871View SEC Filing Icon  
6/15/2021Sell6,000$35.43$212,580.0074,871View SEC Filing Icon  
5/17/2021Sell6,000$31.66$189,960.0074,871View SEC Filing Icon  
4/15/2021Sell6,000$35.06$210,360.0074,871View SEC Filing Icon  
1/26/2021Sell713$39.01$27,814.1356,147View SEC Filing Icon  
9/18/2020Sell2,230$41.18$91,831.4056,860View SEC Filing Icon  
1/28/2020Sell1,478$62.14$91,842.9241,569View SEC Filing Icon  
1/15/2020Sell4,000$68.97$275,880.0045,578View SEC Filing Icon  
12/16/2019Sell4,000$74.59$298,360.0045,578View SEC Filing Icon  
11/15/2019Sell4,000$52.08$208,320.0045,578View SEC Filing Icon  
10/15/2019Sell4,000$42.35$169,400.0045,578View SEC Filing Icon  
9/16/2019Sell4,000$47.26$189,040.0030,578View SEC Filing Icon  
2/15/2019Sell8,000$35.82$286,560.00View SEC Filing Icon  
1/28/2019Sell1,052$31.29$32,917.0826,578View SEC Filing Icon  
See Full Table

Alexander Edward Kuta, III Buying and Selling Activity at uniQure

This chart shows Alexander Edward Kuta III's buying and selling at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

uniQure Company Overview

uniQure logo
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $27.14
Low: $26.73
High: $27.82

50 Day Range

MA: $31.87
Low: $26.42
High: $38.22

2 Week Range

Now: $27.14
Low: $25.80
High: $51.44


342,613 shs

Average Volume

472,958 shs

Market Capitalization

$1.25 billion

P/E Ratio


Dividend Yield



Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!